Achillion Pharmaceuticals (ACHN) 10.06 $ACHN
Achillion presents data on HCV candidates at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 5:18PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
GlobeNewswire - Sat Apr 25, 8:30AM CDT
- Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -
ACHN: 10.06 (+0.06)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals
Steven Giardino - at Seeking Alpha - Mon Apr 20, 12:23PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09)
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), RCPT: 169.88 (-1.26)
Critical Alerts For Tesla Motors, Alcoa, Halliburton, Achillion Pharmaceuticals and Amazon.com Released By InvestorsObserver
PR Newswire - Fri Apr 17, 10:12AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AA, HAL, ACHN and AMZN.
AMZN: 445.10 (+55.11), TSLA: 218.43 (-0.17), AA: 13.22 (+0.03), ACHN: 10.06 (+0.06), HAL: 48.00 (-0.17)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 48.32 (-0.14), AMGN: 167.91 (-1.26), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ACHN: 10.06 (+0.06), AEZS: 0.57 (unch), ANAC: 64.49 (-2.10), XLRN: 33.29 (-0.95)
The Best Stock to Invest in Hep C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:03AM CDT
Source: Gilead Sciences. The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs...
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Technical Analysis on Biotech Equities -- Achillion Pharma, Alexion Pharma, MEI Pharma, MiMedx, and RXi Pharma
PR Newswire - Fri Apr 10, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
RXII: 0.63 (-0.04), ACHN: 10.06 (+0.06), ALXN: 180.08 (-4.50), MDXG: 9.81 (-0.39), MEIP: 2.16 (-0.02)
Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL)
GlobeNewswire - Wed Apr 08, 4:04AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50 Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will include Phase 1 results on ACH-3422, a NS5B nucleotide polymerase inhibitor, and detailed results from the Phase 2 proxy study evaluating ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir following 6- and 8-week treatment durations for treatment-naïve genotype 1 HCV. The congress is being held April 22 - 26 in Vienna, Austria. The abstracts can be accessed on the EASL website at https://ilc-congress.eu/ and posters will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.
ACHN: 10.06 (+0.06)
Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 7:02AM CDT
When it comes to treating hepatitis C, there's no bigger player than Gilead Sciences . Thanks to recent launches of its pan-genotype HCV drug Sovaldi and its genotype 1 therapy Harvoni, Gilead Sciences is dominating the indication, with combined...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex
CBM: 42.97 (+0.37), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), BMY: 65.80 (-0.20)
Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:45AM CDT
Achillion Pharmaceuticals is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
ACHN: 10.06 (+0.06), ACOR: 33.12 (-0.38)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), IBB: 363.70 (-3.98), ABBV: 66.07 (+1.82)
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:50PM CDT
Gilead's (GILD) announced that that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Sovaldi.
CBM: 42.97 (+0.37), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), BMY: 65.80 (-0.20)
Achillion And The Importance Of Hitting The Sweet Spot
Kanak Kanti De - at Seeking Alpha - Wed Mar 25, 1:15PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
Critical Alerts For Sonic, Ross Stores, Potbelly, Achillion Pharmaceuticals and Keryx Biopharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Mar 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SONC, ROST, PBPB, ACHN and KERX.
SONC: 30.83 (-0.21), ACHN: 10.06 (+0.06), PBPB: 14.79 (-0.05), ROST: 104.38 (-0.13), KERX: 11.41 (-0.32)
Achillion Pharmaceuticals' HCV Treatments Are Worth The Investment
Clinically Sound Investor - at Seeking Alpha - Wed Mar 25, 7:01AM CDT
ACHN: 10.06 (+0.06)
Achillion regulatory chief bids adieu
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:06PM CDT
ACHN: 10.06 (+0.06)
3 Things You Need to Know About Achillion Pharmaceuticals Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 22, 10:01AM CDT
Hepatitis C is one of the most attractive indications for drug development, and that could mean hep C-focused Achillion Pharmaceuticals (NASDAQ: ACHN) is perfectly positioned for a blockbuster opportunity. However, that opportunity could be at risk...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
Achillion presents data on HCV candidates at Liver Meeting
Seeking Alpha - at Seeking Alpha - Sat Apr 25, 5:18PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
Achillion Presents Detailed Clinical Results on ACH-3102 and ACH-3422 at the International Liver Congress
GlobeNewswire - Sat Apr 25, 8:30AM CDT
- Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -
ACHN: 10.06 (+0.06)
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)
Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals
Steven Giardino - at Seeking Alpha - Mon Apr 20, 12:23PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09)
3 Biotech Stocks That Could Be Developing Billion Dollar Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 19, 10:07AM CDT
Billion dollar blockbuster status is the Holy Grail pursued by every drugmaker, but developing blockbuster drugs isn't easy. According to the Tufts Center for the Study of Drug Development, it costs $1.4 billion to develop and commercialize a new...
BIIB: 401.71 (-28.57), ESPR: 104.60 (-4.29), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), RCPT: 169.88 (-1.26)
Critical Alerts For Tesla Motors, Alcoa, Halliburton, Achillion Pharmaceuticals and Amazon.com Released By InvestorsObserver
PR Newswire - Fri Apr 17, 10:12AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, AA, HAL, ACHN and AMZN.
AMZN: 445.10 (+55.11), TSLA: 218.43 (-0.17), AA: 13.22 (+0.03), ACHN: 10.06 (+0.06), HAL: 48.00 (-0.17)
Finding Biopharma Licensing and Collaboration Partners: 2015 Guide
M2 - Thu Apr 16, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lwvpxl/finding_biopharma) has announced the addition of the "Finding Biopharma Licensing and Collaboration Partners" report to their offering. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. The report is structured to take the reader step by step through the process of finding and securing partners. However, each chapter is also acts an easy access reference to the particular activity. The report contains numerous checklists and summaries of the contents of key documents required during the partnering process. The report is also provides numerous insights drawn from extensive direct industry experience and knowledge of the author and others. The report provides numerous examples of actual information sources and actual materials utilized by biopharma companies during their partnering efforts, allowing the reader to act on the contents of the report in order to improve their own partnering processes and activities. Key Topics Covered: Chapter 1 - Introduction Chapter 2 - Overview of the partnering process Chapter 3 - Identifying in-licensing opportunities Chapter 4 - Identifying partners Chapter 5 - Building and maintaining a partnering network Chapter 6 - Packaging your offering Chapter 7 - Making contact Companies Mentioned - Partial List - Abbott Japan - Abbott Laboratories - Abraxis BioScience - ACADIA Pharmaceuticals - Acceleron Pharma - Achillion Pharmaceuticals - Adnexus Therapeutics - Adolor - AEterna Zentaris - Affymax - Agensys - Alfacell - Allergan - Ambit Biosciences - Amgen - Amylin Pharmaceuticals - Anacor Pharmaceuticals - Anesiva - Archemix - Ariad Pharmaceuticals - ArQule - Array Biopharma - ARYx Therapeutics - Astellas Pharma - AstraZeneca - Athersys For more information visit http://www.researchandmarkets.com/research/lw..._biopharma
ABT: 48.32 (-0.14), AMGN: 167.91 (-1.26), AGN: 240.22 (+2.88), ACAD: 38.36 (-0.54), ACHN: 10.06 (+0.06), AEZS: 0.57 (unch), ANAC: 64.49 (-2.10), XLRN: 33.29 (-0.95)
The Best Stock to Invest in Hep C
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 16, 7:03AM CDT
Source: Gilead Sciences. The market for hepatitis C treatment is among the most lucrative for drugmakers, but it's also one of the most dynamically changing markets. Only 10 years ago, patients were treated with side effect-laden cocktails of drugs...
JNJ: 101.08 (+0.62), ESRX: 87.34 (+0.45), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), RGLS: 17.49 (-0.80), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20)
Technical Analysis on Biotech Equities -- Achillion Pharma, Alexion Pharma, MEI Pharma, MiMedx, and RXi Pharma
PR Newswire - Fri Apr 10, 8:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
RXII: 0.63 (-0.04), ACHN: 10.06 (+0.06), ALXN: 180.08 (-4.50), MDXG: 9.81 (-0.39), MEIP: 2.16 (-0.02)
Achillion Announces Upcoming Presentations at the International Liver Congress 2015 (EASL)
GlobeNewswire - Wed Apr 08, 4:04AM CDT
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50 Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will include Phase 1 results on ACH-3422, a NS5B nucleotide polymerase inhibitor, and detailed results from the Phase 2 proxy study evaluating ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir following 6- and 8-week treatment durations for treatment-naïve genotype 1 HCV. The congress is being held April 22 - 26 in Vienna, Austria. The abstracts can be accessed on the EASL website at https://ilc-congress.eu/ and posters will be available following their presentation under the resources section of the Achillion website at http://www.achillion.com.
ACHN: 10.06 (+0.06)
Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 01, 7:02AM CDT
When it comes to treating hepatitis C, there's no bigger player than Gilead Sciences . Thanks to recent launches of its pan-genotype HCV drug Sovaldi and its genotype 1 therapy Harvoni, Gilead Sciences is dominating the indication, with combined...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 8:30AM CDT
The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex
CBM: 42.97 (+0.37), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), BMY: 65.80 (-0.20)
Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 30, 7:45AM CDT
Achillion Pharmaceuticals is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
ACHN: 10.06 (+0.06), ACOR: 33.12 (-0.38)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), IBB: 363.70 (-3.98), ABBV: 66.07 (+1.82)
Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 27, 1:50PM CDT
Gilead's (GILD) announced that that the Japanese Ministry of Health, Labour and Welfare has approved its hepatitis C virus (HCV) drug Sovaldi.
CBM: 42.97 (+0.37), GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), BMY: 65.80 (-0.20)
Achillion And The Importance Of Hitting The Sweet Spot
Kanak Kanti De - at Seeking Alpha - Wed Mar 25, 1:15PM CDT
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06)
Critical Alerts For Sonic, Ross Stores, Potbelly, Achillion Pharmaceuticals and Keryx Biopharmaceuticals Released By InvestorsObserver
PR Newswire - Wed Mar 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SONC, ROST, PBPB, ACHN and KERX.
SONC: 30.83 (-0.21), ACHN: 10.06 (+0.06), PBPB: 14.79 (-0.05), ROST: 104.38 (-0.13), KERX: 11.41 (-0.32)
Achillion Pharmaceuticals' HCV Treatments Are Worth The Investment
Clinically Sound Investor - at Seeking Alpha - Wed Mar 25, 7:01AM CDT
ACHN: 10.06 (+0.06)
Achillion regulatory chief bids adieu
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 3:06PM CDT
ACHN: 10.06 (+0.06)
3 Things You Need to Know About Achillion Pharmaceuticals Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sun Mar 22, 10:01AM CDT
Hepatitis C is one of the most attractive indications for drug development, and that could mean hep C-focused Achillion Pharmaceuticals (NASDAQ: ACHN) is perfectly positioned for a blockbuster opportunity. However, that opportunity could be at risk...
GILD: 103.69 (-1.52), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82)
